Rilonacept
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
  (what is this?) (verify) | |
Rilonacept, also known as IL-1 Trap (marketed by Regeneron Pharmaceuticals under the trade name Arcalyst), is an interleukin 1 inhibitor.[1]
Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.[2]
Rilonacept was given an "Orphan Drug" status by the United States Food and Drug Administration and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal onset multisystem inflammatory disease(not approved in the U.S. on this indication).[3]
On May 8th, 2012 an FDA Advisory Panel voted 11-0 against the approval of rilonacept for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug.[4]
References
- ^ http://ard.bmj.com/cgi/content/short/ard.2009.108936v1?rss=1 "The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study " Oct 2009
- ^ "Molecule of the month. Rilonacept". Drug News Perspect. 21 (4): 232. May 2008. PMID 18560622.
- ^ "Arcalyst FDA Approval History - Drugs.com". Retrieved 2012-05-08.
- ^ "Medical News: FDA Panel Nixes Gout Drug - in Rheumatology, General Rheumatology from MedPage Today". Retrieved 2012-05-08.
External links
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |